Issue 12

A STUDY ON THE USE OF DMT TO TREAT DEPRESSION HAS BEEN GIVEN THE GO-AHEAD IN THE UK

The psychedelic compound known as DMT (dimethyltryptamine) will be used in a trial to treat depression for the first time in the United Kingdom.

The study will assess the effectiveness of the compound within a therapeutic setting, following the example of other research projects which have analysed the impact of using psilocybin and ketamine during therapy.

BUSINESS AND INVESTMENT


Psychedelics overtake cannabis as a more popular ‘alternative’ investment.


Mydecine prepares first commercial export of legal psilocybin mushrooms.


PharmaTher files U.S. provisional patent for novel combinations of psilocybin.


Cybin completes acquisition of psychedelic therapeutics company Adelia Therapeutics.


Red Light Holland and Disruptive Pharma announce psychedelic truffle venture in Brazil.


EGF Theramed agrees to acquire LSA company Seedadelic Med Corp.


Tryp Therapeutics files final prospectus and announces IPO on the CSE.


Mind Cure announces its research programme on psilocybin, ketamine and ibogaine.


PharmaTher will meet with FDA for ketamine research in Parkinson’s Disease.


MindMed completes pre-IND meeting with the FDA regarding LSD assisted therapy.


Havn Life announces first pre-clinical study of psilocybin on the immune system.


Psyched Wellness announces successful uplisting to the OTCQB venture market.

PSYTECH SUMMIT

JOIN PSYCH CO-FOUNDER STEPHEN MURPHY AT PSYTECH TODAY

Enjoy access to this exclusive panel discussion focusing on investment opportunities within the psychedelics sector, featuring leaders from across the industry, who will look ahead to the trends which will define 2021 and beyond.

REGULATION & LEGISLATION


Canada allows health professionals to use psilocybin themselves to develop therapies.


Australia prepares to launch world’s first clinical trial of psilocybin on anxiety.


New Jersey State Assembly approves legislation to downgrade psilocybin possession.

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

CONSUMER INSIGHTS, MARKET INTELLIGENCE AND A SCIENTIFIC OVERVIEW OF THE PSYCHEDELICS SECTOR 

The growth of the psychedelics sector has been one of the stand-out developments of 2020 with a plethora of new and innovative studies being carried out on LSD, psilocybin, MDMA, ketamine and ibogaine over the past 12 months.

Early research results have demonstrated the possibility of creating the world’s most exciting healthcare industry in 2021 and beyond.

Download The Psychedelics as Medicine Report: Second Edition to prepare for the year ahead.

RESEARCH AND SCIENCE


Study finds MDMA-assisted psychotherapy to treat alcohol-use disorder to be most effective.


Jordan Peterson talks about Dr Roland Griffith’s research on psilocybin.


Researchers develop a safer version of ibogaine to treat addiction and depression.


Experts favour using psilocybin derivatives for research into mental health treatment.